The main objective of this clinical trial is to assess whether treatment with omega-3 fatty acids can prevent or delay the development of psychosis. Psychosis is a chronic and severe mental disorder that is usually preceded by a period of attenuated psychotic symptoms and functional disorders. Patients can hear voices, see things that are not there or feel like they are being followed.
If you would like to participate, have questions or are interested in the project, please contact us at
E-mail address: Elena.Mueller@med.uni-tuebingen.de
frontend.sr-only_#{element.contextual_1.children.icon}: +49 7071 29-80712
It is a multi-center study that is being conducted in several European countries and Israel. In Germany, the trial centers Jena and Tübingen are participating. The study is initiated, organized and financed by the University Medical Center Utrecht in the Netherlands. Patients between 13 and 20 years of age who have an ultra-high risk of developing psychosis are eligible to participate. The treatment with omega-3 fatty acids or placebo lasts six months. Healthy control participants aged between 13 and 20 years can also participate in the study at the trial center in Tübingen.
Sponsor: Prof. René S. Kahn, Brain Center Rudolf Magnus, Department of Psychiatry, A01.126, University Medical Center Utrecht, The Netherlands
Focus: Top Nationales Krankenhaus 2024
Kooperation für Transparenz und Qualität im Gesundheitswesen
Qualitätspartnerschaft mit der PKV
Erfolgsfaktor Familie
Die Altersvorsorge für den Öffentlichen Dienst
